Application of ginkgo biflavonoids to preparation of medicine for preventing and treating asthma

A technology of ginkgo biflavanoids and compounds, which is applied in the field of medicine, can solve the problems of poor therapeutic effect and severe side effects of asthma drugs, and achieve safe and reliable long-term medication

Inactive Publication Date: 2018-05-08
HUAZHONG UNIV OF SCI & TECH
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] The invention solves the problem of large toxic and side effects or poor therapeutic effect of the drugs for preventing and t

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ginkgo biflavonoids to preparation of medicine for preventing and treating asthma
  • Application of ginkgo biflavonoids to preparation of medicine for preventing and treating asthma
  • Application of ginkgo biflavonoids to preparation of medicine for preventing and treating asthma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Embodiment 1: Extraction of Ginkgo biloba biflavonoids

[0034] Take 500 g of dry ginkgo leaf powder, reflux extraction with 5 L of ether or ethyl acetate twice, recover the solvent, wash the initial extract with petroleum ether until it is colorless, put it on a silica gel column, elute with ethyl acetate, collect the eluent, and obtain Crude Ginkgo Biflavone. Use a certain proportion of pyridine and water to recrystallize the crude product, put it on a silica gel column, elute with a certain proportion of ethyl acetate and methanol, collect the four kinds of biflavones, combine them, and dry them to obtain the yellow dry Solid 7.5 g. The yellow dry solid containing four kinds of ginkgo biflavanoids was taken, dissolved in methanol, and the content detection and impurity analysis were carried out by LC-MS. The liquid phase conditions are as follows:

[0035]

[0036]

[0037] Liquid phase product model: 1100LC / MSD Trap, manufacturer: American Agilent Company, ...

Embodiment 2

[0041] Example 2: Effects of Ginkgo Biflavonoids on Pulmonary Inflammatory Cells in Asthmatic Mice

[0042] According to the asthma model experiment method in "Pharmacological Test Methods", an asthma mouse model was established. Animals: BALB / c mice, 6-8 weeks old, female, weighing 20-25 g. Ovalbumin sensitization, irritability, shortness of breath, abdominal muscle cramps, and fecal incontinence were positive reactions in mice.

[0043]The administration method is as follows: the doses of ginkgo biflavonoids (prepared according to Example 1, including four ginkgo biflavones, HPLC≥90%) are 10 mg / kg, 40 mg / kg, and 80 mg / kg, respectively. The prevention group was administered 2 hours before ultrasonic atomization; the treatment group was administered continuously for 6 days after 15-20 days of atomization.

[0044] Bronchoalveolar lavage fluid (BALF) total cell count and classification detection: After the experiment, the mice were sacrificed, the complete trachea and lungs w...

Embodiment 3

[0048] Example 3: Comparison of ginkgo diflavones and other active ingredients in ginkgo for the prevention and treatment of asthma

[0049] In this implementation, the asthma mouse model is the same as that in Example 2.

[0050] The administration grouping is: the positive control drug is dexamethasone (1mg / kg) (A, A'), and the drugs include: standard ginkgo extract (which contains ginkgo total flavonoid glycosides ≥ 24%, ginkgolide ≥ 6%) ( 10mg / kg (B, B'), 40mg / kg (C, C')) group; Ginkgo biloba (10mg / kg) group (D, D'); Ginkgolide (content ≥ 85%, 2.4mg / kg) group (E, E'); Ginkgo total flavonoid glycosides (content ≥ 85%, 9.6mg / kg) group (F, F'). Each drug is divided into two modes of administration, prevention and treatment. After centrifuging BLFA, take the supernatant, and use the ELASA kit to detect the inflammatory factors IL-4, IL-5, and IL-13 related to asthma.

[0051] For comparison results, see the attached Figure 4 , where the ordinate is the concentration of v...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of ginkgo biflavonoids to preparation of a medicine for preventing and treating asthma. The ginkgo biflavonoids are at least one of 7-demethylated biflavones, ginkgetin, sciadopitysin, and isoginkgetin. The invention discloses a medicinal composition for preventing and treating the asthma, the composition comprises ginkgo biflavonoids, and further comprises at least one of radix glycyrrhizae, white mulberry root-bark and semen armeniacae amarum. The invention further discloses a pharmaceutical composition formed by mixing ginkgo biflavonoids and a pharmaceutically acceptable excipient, and the mass percent of ginkgo biflavonoids is greater than and equal to 2.5%. The ginkgo biflavonoids can inhibit the recruitment of inflammatory cells in lungs, reduce the expression of inflammatory factors in the lungs, and lower the expression of PI3K-related proteins in inflammation pathways, and are free of obvious toxic or side effects and safe and reliable after being taken for a long term.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of ginkgo biloba in the preparation of medicines for preventing and treating asthma. Background technique [0002] Asthma is a chronic inflammation of the airways characterized by reversible bronchospasm and airway hyperresponsiveness. Since the 19th century, people's understanding of the pathogenesis and treatment measures of asthma has made great progress, and the treatment of asthma has made a qualitative leap. Surprisingly, the prevalence and mortality of asthma are still increasing year by year in recent years, and more and more evidence shows that asthma is still a medical problem faced by modern humans. According to a statistical result published in June 2015, about 235 million people worldwide suffer from asthma. It can be seen that it is imminent to find drugs for the control and treatment of asthma. [0003] At present, the development of drugs for the treatme...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/352A61K36/736A61K36/605A61K36/484A61P11/06A61P29/00
CPCA61K31/352A61K36/484A61K36/605A61K36/736A61K2300/00
Inventor 敖明章陶铸余龙江金文闻赵春芳
Owner HUAZHONG UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap